The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
The management of motor neurone disease
Open accessAbstract
he management of motor neurone disease (MND) has evolved rapidly over the last two decades.Although still incurable, MND is not untreatable.From an attitude of nihilism, treatments and interventions that prolong survival have been developed.These treatments do not, however, arrest progression or reverse weakness.They raise difficult practical and ethical questions about quality of life, choice, and end of life decisions.Coordinated multidisciplinary care is the cornerstone of management and evidence supporting this approach, and for symptomatic treatment, is growing.[1][2][3] Hospital based, community rehabilitation teams and palliative care teams can work effectively together, shifting emphasis and changing roles as the needs of the individuals affected by MND evolve.In the UK, MND care centres and regional networks of multidisciplinary teams are being established.Similar networks of MND centres exist in many other European countries and in North America.Here, we review current practice in relation to diagnosis, genetic counselling, the relief of common symptoms, multidisciplinary care, the place of gastrostomy and assisted ventilation, the use of riluzole, and end of life issues.TERMINOLOGY c c Motor neurone disease (MND) is a synonym for amyotrophic lateral sclerosis (ALS).c MND comprises several syndromes (classical or Charcot ALS; progressive bulbar palsy-PBP; progressive muscular atrophy-PMA).c With the exception of primary lateral sclerosis (PLS) all these share the characteristic pathology of MND.The same applies to the ''flail arm'' and ''flail leg'' syndromes (table 1).c MND is used throughout this article, except in relation to the El Escorial criteria. DIAGNOSIS: MAKING IT AND BREAKING ITThe average delay from onset of symptoms to diagnosis is about 14 months, about one third of expected survival.Occasionally, survival following diagnosis may be less than six months.The patient may already suspect the diagnosis and may have visited internet sites or have seen television programmes about people with MND choking to death or demanding the right to assisted suicide.Nevertheless, uncertainty is generally worse than knowing the diagnosis.A diagnosis is usually required before care can be organised.People with suspected MND should be ''fast-tracked'' through the health system to avoid frustrating delays.When the patient is seen for the first time, the diagnosis may be obvious.This poses a dilemma.Should the patient be told, or should one wait until the investigations have been completed?If the individual knows or suspects the diagnosis, it may be best to discuss the possibility of MND, outlining how and when the uncertainty will be resolved.The next step is to exclude other diagnoses (table 2) including rare ''MND mimic'' syndromes (table 3).The El Escorial criteria 4 (box 1) were designed as research diagnostic criteria for clinical trials.Although the criteria strive to codify the process of clinical decision making, patients do not appreciate a diagnosis of ''possible'' or ''probable'' MND.The El Escorial categories of possible and probable ALS (MND) are highly predictive of necropsy proven MND. 5 Thus clinicians can be confident in the diagnosis providing that all the appropriate tests have been done.Routine blood tests are required to exclude other conditions.Examination of the spinal fluid is usually unhelpful, although the total protein may be a little raised.The presence of a significantly raised protein or cell count suggests the need for further investigation to exclude an ALS mimic, such as meningeal infiltration with lymphoma, or (in LMN syndromes) a motor variant of chronic inflammatory demyelinating neuropathy (CIDP).Up to 30% of people in whom MND is diagnosed initially may have other conditions, although in specialist neurological practice the figure is probably about 10%.6 7 Conditions most fre- quently misdiagnosed as MND (table 3) include cervical spondylotic radiculomyelopathy, iv32 www.jnnp.com
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis
Brooks, B. R., Miller, R. G., Swash, M., & Munsat, T. L. (2000) · Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders · doi:10.1080/146608200300079536 · Cited by 5,433
Quality of life in ALS depends on factors other than strength and physical function
Simmons, Z., Bremer, B. A., Robbins, R. A., Walsh, S. M., & Fischer, S. (2000) · Neurology · doi:10.1212/wnl.55.3.388 · Cited by 279
Bach, J. R. (2002) · Chest · doi:10.1378/chest.122.1.92 · Cited by 272
Cited by
Kiernan, M. C., Vucic, S., Cheah, B. C., Turner, M. R., Eisen, A., Hardiman, O., Burrell, J. R., & Zoing, M. C. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61156-7 · Cited by 2,603
van Es, M. A., Hardiman, O., Chio, A., Al-Chalabi, A., Pasterkamp, R. J., Veldink, J. H., & van den Berg, L. H. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31287-4 · Cited by 1,298
The EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis:, Andersen, P. M., Abrahams, S., Borasio, G. D., de Carvalho, M., Chio, A., Van Damme, P., Hardiman, O., Kollewe, K., Morrison, K. E., et al. (2012) · European Journal of Neurology · doi:10.1111/j.1468-1331.2011.03501.x · Cited by 1,117
A comprehensive review of amyotrophic lateral sclerosis
Zarei, S., Carr, K., Reiley, L., Diaz, K., Guerra, O., Altamirano, P., Pagani, W., Lodin, D., Orozco, G., & Chinea, A. (2015) · Surgical Neurology International · doi:10.4103/2152-7806.169561 · Cited by 709
Biomarkers in amyotrophic lateral sclerosis
Turner, M. R., Kiernan, M. C., Leigh, P. N., & Talbot, K. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70293-x · Cited by 438
Self-citation
Metadata
- Authors
- Leigh, P. N.
- Venue
- Journal of Neurology, Neurosurgery & Psychiatry
- Publisher
- BMJ
- Published
- 2003-12-01
- Volume
- 74
- Issue
- 90004
- Pages
- 32iv-47
- ISSN
- 0022-3050 (ISSN-L)
- OpenAlex
- W2126734293
- Cited by
- 226
- References
- 3
- FWCI
- 5.59
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The management of motor neurone disease. https://app.cochat.ai/papers/10.1136/jnnp.74.suppl_4.iv32
- The paper
- Leigh, P. N. (2003). The management of motor neurone disease. Journal of Neurology, Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp.74.suppl_4.iv32
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.